Shripad Dinanath Banavali

12PUBLICATIONS
97CO-AUTHORS
Developmental genetics (incl. sex determination)Cancer therapy (excl. chemotherapy and radiation therapy)Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Infant and child healthPredictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Sep 03, 2026
Clinical Relevance of Genomics Defined WHO5 Subtypes of Pediatric B-ALL in the Context of Measurable Residual Disease-Directed Risk-Based Therapy.

|Jun 17, 2026
Integrating Metronomic Therapy With Standard Chemotherapy in Advanced Unresectable Head and Neck Cancer: A Randomized Trial Addressing Global Cancer Care Equity (METRO PLUS).

|Mar 11, 2026
Carica Papaya Leaf Extract to Improve Chemotherapy-Induced Thrombocytopenia: A Phase III Triple-Blinded, Randomized, Placebo-Controlled, Multicentric Trial.

Vikas Ostwal, Manali Parulekar, Deepali Naughane

|Jan 28, 2026
Efficacy and Safety of Ultra-Low-Dose Immunotherapy in Relapsed Refractory Solid Tumors: Phase III Superiority Randomized Trial (DELII).

Vanita Noronha, Vijay Patil, Nandini Menon

|Jan 21, 2026
PREPARE ALL: An Artificial Intelligence Tool for Predicting Relapse in Children With Acute Lymphoblastic Leukemia.

Subikksha Saravanan, Raghunathan Rengaswamy, Gaurav Narula

|May 22, 2025
Triple Oral Metronomic Chemotherapy Versus Chemotherapy of Physician Discretion After Failure of Platinum-Based Therapy in Advanced Head and Neck Cancer: A Phase III Randomized Study (METRO-CHASE Study).

Akhil Kapoor, Anuj Gupta, Bipinesh Sansar

Pageof 2

Frequent Collaborators

5 joint publications

Vanita Noronha

5 joint publications

Kumar Prabhash

4 joint publications

Gaurav Narula

4 joint publications

Vijay Patil